Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subject and/or subject's legal personal representative fully understand and voluntarily sign informed consent forms;~* 6\~35 years old, all gender;~* Diagnosis of transfusion dependent β-thalassemia (β-TDT) as defined by protocol;~* Eligible for autologous stem cell transplant;~* Organs in good function.~Other protocol defined Inclusion criteria may apply.~Key Exclusion Criteria:~* Subjects with associated α-thalassemia;~* Active bacterial, virus, fungal or parasitic infection, including HIV infection, HbsAg and HBV DNA positive, HCV DNA positive, or Treponema Pallidum infection;~* HLA identical sibling or unrelated donors are available;~* Prior allo-HSCT or gene therapy.~Other protocol defined Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- ET-01 (Type: EXPERIMENTAL): BCL11A Enhancer modified Autologous Hematopoietic Stem Cells

Based on this trial design, predict the completion outcome and termination type (if applicable).